Asset Details
Do you wish to reserve the book?
Cardiovascular Safety of Patisiran Among Transthyretin Cardiac Amyloidosis: A Meta-analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cardiovascular Safety of Patisiran Among Transthyretin Cardiac Amyloidosis: A Meta-analysis
Do you wish to request the book?
Cardiovascular Safety of Patisiran Among Transthyretin Cardiac Amyloidosis: A Meta-analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Cardiovascular Safety of Patisiran Among Transthyretin Cardiac Amyloidosis: A Meta-analysis
2025
Overview
Positively significant results from the phase 3 APOLLO trial have led to its approval for the treatment of variant ATTR amyloidosis with polyneuropathy, which could potentially halt or even reverse neuropathy progression while improv-ing quality of life [1]. [...]it is noteworthy that while efficacy data have been available for patisiran, no pooled meta-analysis has attempted to comprehensively assess its safety profile. [...]we sought to conduct an analysis to provide a comprehensive understanding of the safety profile of patisiran in patients with ATTR amyloidosis. Cardiac magnetic resonance imaging (CMRI) has emerged to be a better diagnostic tooi in suspected cases. Besides diagnosing left ventricular hypertrophy (LVH) phenotypes, it also serves as a crucial modality to monitor disease pro-gression and treatment response. [...]among two randomized trials, patisiran appeared to show a non-significant trend towards reduction in the risk of all-cause mortality and any adverse cardio-vascular events.
Publisher
Springer Nature B.V
